-
In issuing a list of priority for the H1N1 vaccine, European Union health officials have said that people at risk of severe disease, pregnant women and healthcare workers should be given priority for inoculations before the winter flu season because initially there will not be enough vaccine for everyone. The EU has not said whether vaccinations would be mandatory, some countries have ruled this
제약단신
메디칼라이터팀
2009.08.27 00:00
-
According to Amgen Inc. patients with chronic kidney disease, type 2 diabetes and anemia did not benefit from their drug, Aranesp [darbepoetin alfa], in a late stage study. The study of 4,038 patients receiving Aranesp, a treatment of anemia in patients with chronic renal failure, showed that patients fared no better than those who got a placebo on the study"s two main measures. Death from any ca
제약단신
메디칼라이터팀
2009.08.27 00:00
-
The drug plerixafor has been shown to improve stem cell treatment for cancer patients. Physicians have encountered problems collecting enough stem cells from about one in 10 cancer patients but the drug plerixafor enables doctors to collect them in these patients. The drug, which is not licensed yet, works by encouraging the stem cells to enter the blood stream so that doctors can collect them for
제약단신
메디칼라이터팀
2009.08.26 00:00
-
In a letter to Allergan, the FDA has said that a medical journal article from the company is a complete misrepresentation of the results of a study of its acne treatment Aczone [dapsone] and that risk factors are omitted. The FDA expects a written response from the company by August 28 citing an ad that exaggerates the benefit of the drug but according to a spokeswoman for Allergan the ad in quest
제약단신
메디칼라이터팀
2009.08.25 00:00
-
Warner Chilcott will buy Procter & Gamble"s prescription drug business for about $3 billion in a deal financed by 6 banks including Bank of America and JPMorgan Chase. According to data from Dealogic this will be the fourth-largest leveraged loan in the US this year. The deal comes after many months of searching by P&G whose drugs treat bone loss, digestive disorders, and women"s health and will
제약단신
메디칼라이터팀
2009.08.25 00:00
-
의료비 높아도 장기적으로는 비용효과적 원외 심장마비(Out of Hospital Cardiac Arrest, 이하 OHCA) 환자의 생존율은 매우 낮으며 3~40% 정도로 편차가 심한 것으로 알려져 있다. 인구가 밀집돼 있고 조기 심폐소생술이 광범위하게 시행되는 일부 지역에서는 40%를 넘는 생존율을 보이는 한편, 그렇지 않은 지역은 5% 미만을 나타낸다(JAMA 2009;301:860-862). 우리나라의 경우 생존율은 2.4%로 역시 심각한 수준이다. 일반인에 의해서도 적극적으로 심폐소생술이 조기에 시행되는 미국 시애틀, 워싱턴 지역의 43%에 비하면 20 분의 1 수준이며, 일반적으로 선진국들의 생존율인 10% 전후 정도에 비해서도 차이가 크다. 심정지가 발생한 이후 가능한 빨리 시행해야 하는 심폐소생
순환기/뇌혈관
이상돈 기자
2009.08.24 00:00
-
According to WHO"s Western Pacific director, Shin Young-soo, there will be a period of global spread of the virus, and countries may see swine flu cases double every three to four days for several months until peak transmission is reached. Speaking at a symposium of health officials and experts in Beijing, he urged governments to get ready for a quick response to prevent unnecessary deaths from t
제약단신
메디칼라이터팀
2009.08.22 00:00
-
Speaking at a three-day symposium on influenza in the Asia-Pacific region, World Health Organization chief Margaret Chan, has said that a second or even a third wave of swine flu cases was a possibility. She said that limited vaccine supplies could create extremely difficult decisions for governments and that they should be gathering information on priority groups in the event of another round of
제약단신
메디칼라이터팀
2009.08.22 00:00
-
Two small research firms, Legitscript.com and KnujOn.com say that during a three-month period in the spring and early summer of 2009, Yahoo routinely accepted ads from dozens of online pharmacies that dispensed drugs without a valid prescription. Their researchers were able purchase a wide variety of prescription drugs from around a dozen online pharmacy sites that advertised on Yahoo without disc
제약단신
메디칼라이터팀
2009.08.22 00:00
-
The FDA has issued warnings to eight companies who do not have federal permission to market pain relief ointments containing ibuprofen and has given them 15 business days to respond. According to Deborah M. Autor, director of the Office of Compliance at the FDA"s Center for Drug Evaluation and Research, the products have not been evaluated for safety, effectiveness and potential side-effects. The
제약단신
메디칼라이터팀
2009.08.22 00:00
-
An industry funded study has shown that patients who received preventive treatment for venous thromboembolic disease (VTE) with the anticoagulant enoxaparin, a low molecular weight heparin sold as Lovenox and Clexane, incurred lower hospital costs than if they were treated with unfractionated heparin (UFH). According to data appearing in the Journal of Thrombosis and Thrombolysis, hospital costs o
제약단신
메디칼라이터팀
2009.08.22 00:00
-
Hiberix, a vaccine that helps prevent the bacterial infection Haemophilus influenzae type b (Hib) which can cause meningitis, was approved by the FDA as the fourth booster dose for children 15 months to four years old. The GlaxoSmithKline PLC vaccine was given accelerated approval due to a shortage of the vaccine after Merck & Co. Inc. withdrew 1.2 million doses in 2007 because of suspected contam
제약단신
메디칼라이터팀
2009.08.22 00:00
-
Pfizer Inc. and the information technology company, Private Access intend to create a website where patients can find out about clinical trials, and where physicians, researchers, and drug companies can look for test subjects. Patients will be able to use privacy options so that selected personal information is only available to researchers on specific illnesses that are of interest to them and ac
제약단신
메디칼라이터팀
2009.08.21 00:00
-
A study concludes that Iressa [gefitinib] can slow the deadly nonsmall-cell lung cancer (NSCLC) better than standard chemotherapy in patients who have the epidermal growth factor receptor (EGFR) gene mutation. According to lead investigator Tony S. Mok, MD, from the Chinese University of Hong Kong, the presence of an EGFR mutation was a robust predictor of improved progression-free survival with
제약단신
메디칼라이터팀
2009.08.21 00:00
-
In analyzing prescription data for 39,736 patients aged 66 and over who began taking Avandia [rosiglitazone] or Actos [pioglitazone] from April 2002 to March 2008 investigators found that 6.9 percent of patients taking GlaxoSmithKline Plc"s Avandia died or were hospitalized for a heart attack or heart failure, compared with 5.3 percent of those on Takeda Pharmaceutical Co."s rival diabetes drug,
제약단신
메디칼라이터팀
2009.08.20 00:00
-
A study of the HPV vaccine Gardasil where CDC researchers analyzed 12,424 reports of side effects following injection with the vaccine has appeared in the Journal of the American Medical Association. The vaccine was approved in 2006 and 23 million doses have been given. Most of the side effects were mild and included dizziness, headache, and fainting but the study included more than 700 reports of
제약단신
메디칼라이터팀
2009.08.20 00:00
-
US health officials had predicted 120 million doses of the H1N1 vaccine would be available by mid-October when the mass vaccination campaign is due to begin but it has now said that there will only be 45 million doses available. According to Dr. William Schaffner of the Vanderbilt University Medical Center, the delay gives the virus a slight advantage and guidelines will need to be explicit about
제약단신
메디칼라이터팀
2009.08.19 00:00
-
Hospira has stopped shipping the generic version of Eloxatin [oxaliplatin] injection, just days after the company received FDA approval due to court proceedings filed by the branded drugmaker, Sanofi-Aventis over the drug"s patent. According to Hospira the shipping suspension is temporary and the drug"s safety and efficacy is not being questioned.
제약단신
메디칼라이터팀
2009.08.19 00:00
-
Researchers found that of 48,785 HIV patients who received free treatment under a government program in China from 2002 to 2008, AIDS- related deaths were slowed but the drugs failed to treat 50 percent of the group over the period. According to a report in the Annals of Internal Medicine China"s AIDS patients do not have access to the support drugs that are available in developed nations.
제약단신
메디칼라이터팀
2009.08.19 00:00
-
Vectibix [panitumumab], has been tested on 1,186 patients with colon cancer in combination with chemotherapy as a second-line treatment, and according to Amgen Inc., the drug"s maker, it has met the key treatment goals. Past research has shown that both Vectibix and Erbitux [cetuximab] are ineffective in patients whose tumors have mutant versions of the KRAS gene so all participants had tumors wi
제약단신
메디칼라이터팀
2009.08.19 00:00